Traitement en cours

Veuillez attendre...

Paramétrages

Paramétrages

1. WO2012012141 - PROTÉINES DE FUSION SCNN1A/TNFRSF1A DANS LE CANCER

Numéro de publication WO/2012/012141
Date de publication 26.01.2012
N° de la demande internationale PCT/US2011/042201
Date du dépôt international 28.06.2011
CIB
C07K 16/28 2006.01
CCHIMIE; MÉTALLURGIE
07CHIMIE ORGANIQUE
KPEPTIDES
16Immunoglobulines, p.ex. anticorps monoclonaux ou polyclonaux
18contre du matériel provenant d'animaux ou d'humains
28contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire
C07K 16/30 2006.01
CCHIMIE; MÉTALLURGIE
07CHIMIE ORGANIQUE
KPEPTIDES
16Immunoglobulines, p.ex. anticorps monoclonaux ou polyclonaux
18contre du matériel provenant d'animaux ou d'humains
28contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire
30provenant de cellules de tumeurs
C07K 14/705 2006.01
CCHIMIE; MÉTALLURGIE
07CHIMIE ORGANIQUE
KPEPTIDES
14Peptides ayant plus de 20 amino-acides; Gastrines; Somatostatines; Mélanotropines; Leurs dérivés
435provenant d'animaux; provenant d'humains
705Récepteurs; Antigènes de surface cellulaire; Déterminants de surface cellulaire
CPC
A61K 47/67
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
47Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
50the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
51the non-active ingredient being a modifying agent
62the modifying agent being a protein, peptide or polyamino acid
66the modifying agent being a pre-targeting system involving a peptide or protein for targeting specific cells
67Enzyme prodrug therapy, e.g. gene directed enzyme drug therapy [GDEPT] or VDEPT
A61K 47/6869
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
47Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
50the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
51the non-active ingredient being a modifying agent
68the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
6835the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
6851the antibody targeting a determinant of a tumour cell
6869the tumour determinant being from a cell of the reproductive system: ovaria, uterus, testes, prostate
B82Y 5/00
BPERFORMING OPERATIONS; TRANSPORTING
82NANOTECHNOLOGY
YSPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
5Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
C07K 14/4748
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
14Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
435from animals; from humans
46from vertebrates
47from mammals
4701not used
4748Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
C07K 14/705
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
14Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
435from animals; from humans
705Receptors; Cell surface antigens; Cell surface determinants
C07K 14/70578
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
14Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
435from animals; from humans
705Receptors; Cell surface antigens; Cell surface determinants
70578NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
Déposants
  • AMGEN INC. [US/US]; One Amgen Center Drive Thousand Oaks, California 91320, US (AllExceptUS)
  • QUON, Kim Coign [CA/US]; US (UsOnly)
  • CUTLER, Gene [US/US]; US (UsOnly)
  • KORDICH, Jennifer Joy [US/US]; US (UsOnly)
Inventeurs
  • QUON, Kim Coign; US
  • CUTLER, Gene; US
  • KORDICH, Jennifer Joy; US
Mandataires
  • SMITH, Julie K.; Amgen Inc. Law Department 1201 Amgen Court West Seattle, Washington 98119, US
Données relatives à la priorité
61/360,38130.06.2010US
61/501,08024.06.2011US
Langue de publication anglais (EN)
Langue de dépôt anglais (EN)
États désignés
Titre
(EN) SCNN1A/TNFRSF1A FUSION PROTEINS IN CANCER
(FR) PROTÉINES DE FUSION SCNN1A/TNFRSF1A DANS LE CANCER
Abrégé
(EN)
The present invention provides fusion proteins expressed by cancer cells, antibodies and other antigen -binding agents that specifically bind to the fusion proteins, and compositions and methods for using the antibodies and other antigen-binding agents to detect, characterize, and treat cancer.
(FR)
La présente invention concerne des protéines de fusion exprimées par des cellules cancéreuses, des anticorps et d'autres agents se liant aux antigènes se liant spécifiquement aux protéines de fusion, et des compositions et des méthodes d'utilisation des anticorps ou des autres agents se liant aux antigènes dans la détection, la caractérisation et le traitement du cancer.
Également publié en tant que
Dernières données bibliographiques dont dispose le Bureau international